By the end of this month, we'll have worked our way through the special series of Business of Biotech episodes recorded and filmed on-site at the JP Morgan Healthcare conference, where we were graciously hosted by some wonderful lawyers (those words don't have to be mutually exclusive) at the law offices of Alston & Bird.
Big thanks to those folks, and to Life Science Leader's Ben Comer for joining me on several of these. Ben and I have some big news coming at the end of the month, so make sure you don't miss the episode we drop on 3/31!
If you're not already listening to the podcast, subscribe wherever you like, or better yet, watch our videocasts here. Stay as long as you like. There are hundreds of them.
This month's edition of the Business of Biotech newsletter features a few of our favorite guests from our time in San Fran, as well as the usual batch of Life Science Connect insight I hand-picked for Business of Biotech listeners. Enjoy, and happy Spring!
Matt Pillar, Business of Biotech host and chief editor, Bioprocess Online |
|
| | Biotech Beat | March 18, 2025 |
|
| ![]() | | by RICHARD MORONEY, PH.D. | As if managing supplier relationships wasn't bumpy enough, biopharmas are now navigating all sorts of turbulence-causing geopolitical pressures, particularly in outsourced manufacturing. Brand-new Bioprocess Online contributor Richard Moroney, Ph.D. wrote a super helpful column on building the resilience necessary to handle what he gently calls "dynamic" vendor relationships. | READ NOW → |
|
![]() | | by BEN COMER | This Ben Comer (Life Science Leader) column features an interview with Kurt Erskine, government investigations chair at the law firm Polsinelli, who says biopharmas “can’t have an on the shelf compliance program" in the face of the evolving Foreign Corrupt Practices Act. As is often the case, the former DOJ attorney says whether the Trump administration likes it or not, it's not going away, so global biopharma beware. | READ NOW → |
|
| ![]() | | by ANNA ROSE WELCH | There's more Anna Rose Welch (Advancing RNA) coming to the Business of Biotech podcast, I promise. In the meantime, here's her latest column on the role of CDMOs in the fast-moving RNA therapeutics space. It's replete with a well-executed Aladdin-inspired storyline, because what else would you expect from Anna Rose Welch? | READ NOW → |
|
![]() | | by DAN SCHELL | In biotech, molecular and target discovery get all the AI attention, polarizing as the topic remains. But my friend and colleague Dan Schell (Clinical Leader) says the tech is making big waves in clinical trials, too, and its use cases there don't look quite as contentious -- at least, not from afar. Dan recently hosted a panel discussion on the topic that drew nearly 800 registrants. Here, he writes about what was on their minds. | READ NOW → |
|
| | "It's kind of fancy to prognosticate and say, 'this is exactly the type of investor that I want to have in this company.' At the end of the day, you have to eat the food that's on the table." | ― Tom Chalberg, Ph.D., Founder, Chairman, & CEO, Genascence, Episode 242 |
|
| "In the pure academic setting, there's not necessarily a roadmap of how to commercialize and go after therapeutic development. It's always been known as this valley of death between academics and industry." | ― Brad Sitko, Chief Investment Officer, XOMA Royalty, Episode 243 |
|
| "We sold everything. My wife was, of course, not excited about it, but came along for the ride. And we put the strollers on top of the van and moved cross country, and for the next two-ish years, everything was at risk." | ― Rick Modi, CEO, Affinia Therapeutics, Episode 244 |
|
| | | ![]() | Created exclusively for the leaders of new and emerging biopharma firms, the Business of Biotech podcast tackles organizational, funding, HR, regulatory, production and CMC considerations with insight from peer founders who have taken biologic therapies from an idea to clinical success. Check out our episode archive. | |
|
|
|
Stay versed in all things biotech - developments, products, services, and the individuals setting the pace. The Life Science Connect community offers its subscribers an assemblage of resources from discerning editorial to interactive webinars, entertaining podcasts to supplier white papers, and more. |
|
|
|
Ensure our newsletter reaches your inbox by following these whitelist instructions.
This newsletter is being sent to {{lead.Email Address}}. To cancel your subscription to the newsletter, please opt out. | © Copyright 2024 Vertmarkets, Inc. 5340 Fryling Rd Suite 100, Erie, PA 16510.
All rights reserved. All product names contained herein are the trademarks of their respective holders. |
|
|
|
|
